Details of the Drug Therapeutic Target (DTT)
General Information of Drug Therapeutic Target (DTT) (ID: TT6Y1PG)
| DTT Name | Solute carrier family 40 member 1 (SLC40A1) | ||||
|---|---|---|---|---|---|
| Synonyms | SLC11A3; MSTP079; IREG1; Ferroportin-1; FPN1 | ||||
| Gene Name | SLC40A1 | ||||
| DTT Type |
Clinical trial target
|
[1] | |||
| BioChemical Class |
Ferroportin protein
|
||||
| UniProt ID | |||||
| TTD ID | |||||
| 3D Structure | |||||
| Sequence |
MTRAGDHNRQRGCCGSLADYLTSAKFLLYLGHSLSTWGDRMWHFAVSVFLVELYGNSLLL
TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKHEL LTMYHGWVLTSCYILIITIANIANLASTATAITIQRDWIVVVAGEDRSKLANMNATIRRI DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYVLLWKVYQKTPALAVKAGLK EEETELKQLNLHKDTEPKPLEGTHLMGVKDSNIHELEHEQEPTCASQMAEPFRTFRDGWV SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSILMGASAITGIMGTVAF TWLRRKCGLVRTGLISGLAQLSCLILCVISVFMPGSPLDLSVSPFEDIRSRFIQGESITP TKIPEITTEIYMSNGSNSANIVPETSPESVPIISVSLLFAGVIAARIGLWSFDLTVTQLL QENVIESERGIINGVQNSMNYLLDLLHFIMVILAPNPEAFGLLVLISVSFVAMGHIMYFR FAQNTLGNKLFACGPDAKEVRKENQANTSVV |
||||
| Function |
Mediates iron efflux in the presence of a ferroxidase (hephaestin and/or ceruloplasmin). May be involved in iron export from duodenal epithelial cell and also in transfer of iron between maternal and fetal circulation.
|
||||
| KEGG Pathway | |||||
| Reactome Pathway | |||||
Molecular Interaction Atlas (MIA) of This DTT
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
3 Clinical Trial Drug(s) Targeting This DTT
|
||||||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) of This DTT
The Drug Transporter (DTP) Role of This DTT
| DTT DTP Name | Iron-regulated transporter 1 (SLC40A1) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene Name | SLC40A1 | |||||||||||||||||||||||||||
|
1 Approved Drug(s) Transported by This DTT
|
||||||||||||||||||||||||||||
References
| 1 | The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161. | ||||
|---|---|---|---|---|---|
| 2 | Targeting the Hepcidin-Ferroportin Axis to Develop New Treatment Strategies for Anemia of Chronic Disease and Anemia of Inflammation. Am J Hematol. 2012 April; 87(4): 392-400. | ||||
| 3 | Hepcidin agonists as therapeutic tools. Blood. 2018 Apr 19;131(16):1790-1794. | ||||
| 4 | Ferroportin-mediated iron transport: expression and regulation. Biochim Biophys Acta. 2012 Sep;1823(9):1426-33. | ||||
